Hepatect Cp (Human Hepatitis B Immunoglobulin)

Hepatect Cp is indicated for several clinical situations where passive immunity against hepatitis B virus is required.

• Post‑exposure prophylaxis after known or suspected exposure to hepatitis B virus.
• Prevention of hepatitis B virus recurrence in patients undergoing liver transplantation.
• Prophylaxis of newborns born to hepatitis B‑positive mothers when administered with hepatitis B vaccine.
• Protection of healthcare workers after occupational exposure to hepatitis B infected blood or body fluids.
• Supplementary protection for individuals with inadequate response to hepatitis B vaccination.

Side effects of Hepatect Cp are generally related to the infusion process and immune response.

Common

• Mild fever or chills during or shortly after infusion.
• Headache or fatigue.
• Localized pain or erythema at the infusion site.
• Nausea or mild gastrointestinal discomfort.
• Transient elevations in liver enzymes.

Serious

• Severe allergic reactions, including anaphylaxis.
• Acute hemolysis.
• Renal impairment or acute kidney injury.
• Thromboembolic events.
• Severe hypotension or cardiovascular collapse.
• Disseminated intravascular coagulation (DIC).

When prescribing Hepatect Cp, clinicians should consider several safety factors.

• Assess patient history for prior hypersensitivity to human immunoglobulins or blood products.
• Monitor vital signs and for signs of allergic reaction during the first infusion.
• Use caution in patients with renal insufficiency or a history of thromboembolic disease.
• Evaluate liver function tests before and during therapy, especially in transplant recipients.
• Avoid use in individuals with uncontrolled hypertension or active bleeding disorders.
• Pregnancy and lactation status should be reviewed, as safety data are limited.

Hepatect Cp may interact with other medications or clinical conditions.

Avoid

• Concurrent administration of other blood‑derived products without appropriate monitoring.
• Use with known anaphylactogenic agents in patients with a history of severe allergic reactions.

Use with caution

• Immunosuppressive agents, as they may alter the efficacy of passive immunity.
• Anticoagulants, due to potential increased risk of bleeding at the infusion site.
• Nephrotoxic drugs, because of added renal stress.
• Vaccines other than hepatitis B vaccine, to avoid interference with immune response.
• High‑dose corticosteroids, which may mask infusion‑related reactions.